Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked Randomized Clinical Trial
● PURPOSE: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin) to ranibizumab (Lucentis) for the treatment of age-related macular degeneration.
● DESIGN: Prospective, double-masked, randomized clinical trial.
● CONCLUSION: Early results of a head-to-head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of agerelated macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance.
Posts
Post a Comment